GRAIL, Inc. (GRAL)
| Market Cap | 2.67B +103.2% |
| Revenue (ttm) | 156.12M +19.4% |
| Net Income | -395.33M |
| EPS | -10.31 |
| Shares Out | 42.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,838 |
| Open | 60.02 |
| Previous Close | 61.26 |
| Day's Range | 60.02 - 62.33 |
| 52-Week Range | 29.95 - 118.84 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 68.57 (+10.31%) |
| Earnings Date | May 5, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $68.57, which is an increase of 10.31% from the latest price.
News
Grail price target lowered to $70 from $82 at Baird
Baird lowered the firm’s price target on Grail (GRAL) to $70 from $82 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results. Published…
Grail price target raised to $56 from $54 at Piper Sandler
Piper Sandler raised the firm’s price target on Grail (GRAL) to $56 from $54 and keeps a Neutral rating on the shares. The firm notes the company delivered Q1 beat…
Grail price target raised to $69 from $65 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Grail (GRAL) to $69 from $65 and keeps a Buy rating on the shares. The firm said they posted…
Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking
Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo G...
Grail reports Q1 EPS ($2.29), consensus ($1.96)
Reports Q1 revenue $40.8M, consensus $39.15M. “GRAIL (GRAL) continues to execute commercially, with strong volume growth in Q1. We continue to build new partnerships to support demand and were pleased...
GRAIL Earnings Call Transcript: Q1 2026
Q1 2026 saw 50% test volume growth and 37% screening revenue growth, with strong adoption across providers and digital health. FDA review of Galleri is underway, Salesforce expansion is on track, and full-year revenue guidance is reiterated at 22–32%.
GRAIL Reports First Quarter 2026 Financial Results
Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platf...
GRAIL to Present at the BofA Securities 2026 Health Care Conference
MENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL to Announce First Quarter 2026 Financial Results
MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Prese...
Grail initiated with a Neutral at Mizuho
Mizuho analyst Bradley Bowers initiated coverage of Grail (GRAL) with a Neutral rating and $58 price target Grail is a leader in multicancer early detection testing with its Galleri test…
Grail initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Grail (GRAL) with a Neutral rating and $54 price target The company holds the largest clinical datasets of any company in the multi-cancer early detection…
Grail announces collaboration with Epic to bring Galleri test to EHR platforms
Grail (GRAL) announced a collaboration with Epic to bring the Galleri multi-cancer early detection test into one of the nation’s most widely used electronic health record platforms, supporting broader...
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the G...
Grail, Superpower partner to expand early cancer detection
Superpower announced a strategic partnership with GRAIL (GRAL) to bring members access to the Galleri multi-cancer early detection test. The Galleri test is available as an add-on through the Superpow...
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
Partnership expands access to breakthrough blood-based cancer screening intoSuperpower's comprehensive health check and personalized plans. SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the...
Grail price target lowered to $75 from $130 at Guggenheim
Guggenheim lowered the firm’s price target on Grail (GRAL) to $75 from $130 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
Grail upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Dan Brennan upgraded Grail (GRAL) to Buy from Hold with a price target of $65, down from $114. The firm believes the recent selloff in the shares…
Grail CEO Bob Ragusa to retire, Josh Ofman named successor
Cancer test maker Grail said on Thursday that chief executive Bob Ragusa will retire effective June 1, and the company's president, Josh Ofman, will take over the helm.
Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor
Grail (GRAL) announced that Bob Ragusa will retire as CEO effective June 1. The board has appointed the company’s President, Josh Ofman, to serve as Grail’s CEO upon Ragusa’s retirement.
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will r...
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time Investigation examines whether Grail's forward guidance omitted material headwinds kn...
GRAIL Transcript: TD Cowen 46th Annual Health Care Conference
NHS-Galleri trial data showed strong stage IV cancer reduction and improved detection rates, supporting regulatory and commercial momentum. FDA approval and CMS reimbursement are expected to hinge on clinical utility, with robust evidence from ongoing and completed studies. The self-pay and digital health markets are expanding rapidly.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif., March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equ...
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...